| Literature DB >> 24349119 |
Tekeshe A Mekonnen1, Michelle C Odden2, Pamela G Coxson1, David Guzman1, James Lightwood3, Y Claire Wang4, Kirsten Bibbins-Domingo5.
Abstract
BACKGROUND: Consumption of sugar-sweetened beverage (SSB) has risen over the past two decades, with over 10 million Californians drinking one or more SSB per day. High SSB intake is associated with risk of type 2 diabetes, obesity, hypertension, and coronary heart disease (CHD). Reduction of SSB intake and the potential impact on health outcomes in California and among racial, ethnic, and low-income sub-groups has not been quantified.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24349119 PMCID: PMC3859539 DOI: 10.1371/journal.pone.0081723
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Framework for the impact of an SSB tax on health outcomes.
Model assumptions.
| Risk Factors/inputs | Effect size | Reference | |
| Serving size of a SSB | 12 fl. Oz | ||
| Proportion of calories compensated for by other beverages, after a reduction in SSB | 39% |
| |
| Relative risk of diabetes associated with consuming one or more SSB per day(95% CI) | 1.35 (95% CI: 1.14, 1.59) |
| |
| Proportion of increased risk assumed to be mediated through BMI | 50% |
| |
| Change per 1 unit increase of (BMI) | Men | Women |
|
| Systolic blood pressure, (95% CI) | 1.43 | 1.24 | |
| Cholesterol (mg/dl) | |||
| Low-density lipoprotein | 2.75 | 2.24 | |
| High-density lipoprotein | −1.55 | −0.77 | |
| Diabetes (per unit BMI) | 1.26 | 1.30 | |
| Change in systolic blood pressure due to a reduction in SSB consumption of 1serving/day, mmHg (95% CI) | −0.78 (95% CI: 0.09, 1.47) | −0.61 (95% CI: −0.27,1.48) |
|
| Change in consumption by elasticity estimate, assuming a pre-tax price of $1.00 | −0.79 to −1.00 |
| |
Sugar-sweetened beverages.
Hazard ratio.
β coefficients.
Figure 2Projected incident diabetes decrease at different levels of SSB consumption reduction with variation of BMI effects.
Absolute number of coronary heart disease events and deaths prevented from a 10–20% SSB consumption reduction with moderate BMI effects from 2013–2022 in California (Percent change).
| Absolute number of anticipated cases before reduced SSB consumption | 10% reduction in SSB consumption | 20% reduction in SSB consumption | ||
| Incident coronary heart disease (CHD) | 1,140,000 | −6,000 (−0.5%) | −12,000 (−1.0%) | |
| Total myocardial infarction (MI) | 560,000 | −2,700 (−0.5%) | −5,300 (−0.9%) | |
| CHD mortality | 336,000 | −1,300 (−0. 4%) | −2,500 (−0.7%) | |
| Death from any cause | 1,668,000 | −1,600 (−0.1%) | −3,200 (−0.2%) | |
Assumes 39% caloric compensation that will result from replacing 1/3 of the reduced SSB consumption with water, 1/3 with diet drinks, and the remaining 1/3 with other caloric beverages such as milk and juice.
Includes new and recurrent myocardial infarctions.
Absolute number of events and deaths prevented from a 10% SSB consumption reduction under worst and best case scenarios from 2013–2022 in California (Percent change).
| Absolute number of anticipated cases before reduced SSB consumption | Minimal Estimated Effect | Maximal Estimated Effect | |
| Incident diabetes | 666,000 | −1,900 (−.29%) | −18,200 (−2.73%) |
| Incident coronary heart disease (CHD) | 1,140,000 | −120 (−0.01%) | −9,700 (−0.85%) |
| Total myocardial infarction (MI) | 560,000 | −50 (−0.01%) | −4,400 (−0.79%) |
| CHD mortality | 336,000 | −20 (−0.01%) | −2,100 (−0.62%) |
| Death from any cause | 1,667,000 | −60 (−0.00%) | −2,700 (−0.16%) |
Assumes a moderate BMI effect of the reduction in SSB consumption: 39% caloric compensation that will result from replacing 1/3 of the reduced SSB consumption with water, 1/3 with diet drinks, and the remaining 1/3 with other caloric beverages such as milk and juice.
Includes new and recurrent myocardial infarctions.
Minimal estimated effect was calculated based on no BMI effect, an adjusted RR of diabetes of 1.07 per SSB serving per day, and a 0.09 mmHg reduction in systolic blood pressure in men only.
Maximal estimated effect was calculated based on a strong BMI effect, an adjusted RR of diabetes of 1.26 per SSB serving per day, and a 1.47 and 1.48 mmHg reduction in systolic blood pressure in men and women, respectively.
Figure 3Projected decrease in annual incident diabetes at 10% SSB consumption reduction in subgroups of California.
Projected difference in event rates per million person-years after a 10% SSB consumption reduction, across subgroups of California (Percent change).
| AllCalifornians | AfricanAmericans | MexicanAmericans | LowSES | |
| Incident coronary heart disease (CHD) | −35 (−0.54%) | −56 (−0.64%) | −73 (−0.98%) | −53 (−76%) |
| Total myocardial infarction (MI) | −17 (−0.52%) | −41 (−0.87%) | −33 (−0.93%) | −27 (−0.77%) |
| CHD mortality | −8 (−0.43%) | −20 (−0.63%) | −16 (−0.77%) | −13 (−0.61%) |
| Death from any cause | −13 (−0.14%) | −24 (−0.12%) | −29 (−0.31%) | −23 (−0.19%) |
Assumes a moderate BMI effect of the reduction in SSB consumption: 39% caloric compensation that will result from replacing 1/3 of the reduced SSB consumption with water, 1/3 with diet drinks, and the remaining 1/3 with other caloric beverages such as milk and juice.
<200% of the Federal Poverty Level.
Includes new and recurrent myocardial infarctions.
Projected healthcare savings from 2013–2022 after a 10–50% SSB consumption reduction with a moderate BMI effect, in 2012 US dollars – in millions (Percent change).
| Diabetes | Diabetes-related coronary heartdisease (CHD) | Total coronary heart disease (CHD) | |
| 10% reduction in SSB consumption | −$318 (−1.0%) | −$14 (−0.01%) | −$555 (−0.4%) |
| 20% reduction in SSB consumption | −$622 (−2.0%) | −$27 (−0.03%) | −$1,066 (−0.7%) |
| 50% reduction in SSB consumption | −$1,480 (−4.7%) | −$66 (−0.07%) | −$2,591 (−1.6%) |
Assumes 39% caloric compensation that will result from replacing 1/3 of the reduced SSB consumption with water, 1/3 with diet drinks, and the remaining 1/3 with other caloric beverages such as milk and juice.
Diabetes cost is adjusted to only reflect diabetes direct healthcare costs.
Diabetes related CHD cost represents excess CHD that could be avoided as a result of the avoided diabetes cases from reduced SSB consumption.
Reflects total CHD treatment cost.